TradeFlare's AI research teams analysed CNTA on 9 market nights between June 5, 2026 and June 25, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| June 25, 2026 | BUY | $40.50 | — / — | not yet | not yet | The market is neutral, and while the technicals are bullish, the strong fundamental and sentiment bearishness, coupled with high risk, necessitate a cautious approach. |
| June 24, 2026 | SELL | $40.50 | — / — | not yet | not yet | Eli Lilly's acquisition of Centessa Pharmaceuticals is progressing, providing a clear exit for shareholders. |
| June 23, 2026 | BUY | $40.18 | $48.22 / $34.15 | not yet | not yet | The acquisition by Eli Lilly provides a clear catalyst with a defined timeline for deal completion. |
| June 22, 2026 | BUY | $40.02 | — / — | not yet | not yet | Eli Lilly acquisition offers a clear price floor and potential upside. |
| June 19, 2026 | HOLD | $40.02 | $47.62 / $34.02 | not yet | not yet | The stock is near a 52-week high with a pending acquisition, suggesting potential for short-term volatility and price discovery. |
| June 18, 2026 | BUY | $39.87 | — / — | not yet | not yet | The stock is currently in a neutral market regime and the risk profile is too high for a buy recommendation given the conflicting team scores. |
| June 17, 2026 | BUY | $39.75 | $45.71 / $33.79 | not yet | not yet | The acquisition news provides a near-term catalyst, but the stock needs to break out and sustain momentum. |
| June 10, 2026 | BUY | $39.76 | — / — | not yet | not yet | Eli Lilly acquisition offer provides a significant valuation anchor. |
| June 5, 2026 | HOLD | $39.80 | — / — | not yet | not yet | Eli Lilly's acquisition agreement provides a clear near-term catalyst. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.